We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for ripretinib (Tudorrose Consulting Pty Ltd)
Active ingredients
ripretinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of patients with advanced gastrointestinal stromal tumours (GIST), who have received prior treatment with imatinib, sumitinib and regorafenib.
Therapeutic area
Oncology